Hims & Hers Health (NYSE:HIMS) Trading 6.7% Higher

Hims & Hers Health, Inc. (NYSE:HIMS) rose 6.7% during mid-day trading on Thursday . The company traded as high as $16.32 and last traded at $16.29. Approximately 3,240,439 shares traded hands during trading, a decline of 58% from the average daily volume of 7,757,520 shares. The stock had previously closed at $15.27.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Canaccord Genuity Group upped their price target on Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Bank of America increased their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Truist Financial lifted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Jefferies Financial Group upped their price target on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, June 27th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $18.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health presently has an average rating of “Moderate Buy” and a consensus price target of $20.29.

Hims & Hers Health Trading Up 4.9 %

The company has a market cap of $3.44 billion, a P/E ratio of -1,606.00 and a beta of 1.06. The company’s fifty day moving average is $17.97 and its 200 day moving average is $16.92.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The company had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. During the same period in the prior year, the business posted ($0.03) EPS. Hims & Hers Health’s quarterly revenue was up 51.8% compared to the same quarter last year. Analysts anticipate that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, COO Melissa Baird sold 11,749 shares of Hims & Hers Health stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $14.65, for a total value of $172,122.85. Following the sale, the chief operating officer now owns 585,800 shares in the company, valued at $8,581,970. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Michael Chi sold 7,500 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $24.50, for a total transaction of $183,750.00. Following the sale, the insider now directly owns 185,326 shares in the company, valued at $4,540,487. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Melissa Baird sold 11,749 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $14.65, for a total value of $172,122.85. Following the completion of the sale, the chief operating officer now directly owns 585,800 shares in the company, valued at $8,581,970. The disclosure for this sale can be found here. Insiders sold 753,292 shares of company stock valued at $13,557,329 in the last 90 days. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its stake in shares of Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC boosted its stake in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares during the last quarter. Van ECK Associates Corp bought a new stake in shares of Hims & Hers Health during the 2nd quarter valued at $111,000. Amalgamated Bank increased its stake in shares of Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares in the last quarter. Finally, Daiwa Securities Group Inc. bought a new position in Hims & Hers Health in the 2nd quarter worth $142,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.